CoChat

O1‐10‐06: Results From a First‐in‐Human Study with the Bace Inhibitor CNP520

Ufer, Mike, Rouzade-Dominguez, Marie-Laure, Huledal, Gunilla, Pezous, Nicole, Avrameas, Alexandre, David, Olivier, Kretz, Sandrine, Kucher, Klaus, Neumann, Ulf, Cha, Jang-Ho, Graf, Ana, Lopez-Lopez, Cristina · 2016 · Alzheimer's & Dementia
Cited by 9

The DOI matches its Crossref record.

Abstract

CNP520 inhibits the β-site APP cleaving enzyme 1 (BACE-1), leading to reduced formation of amyloid-β (Aβ). It is under clinical development as potentially disease-modifying treatment in asymptomatic subjects at risk of developing Alzheimer’s disease because of their ApoE genotype. This randomized, double-blind, placebo-controlled, first-in-human (FiH) study has been conducted to assess the safety/tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of single- and multiple ascending doses of CNP520. Single ascending doses were orally administered to healthy adults (n=38/14 CNP520/placebo) and elderly subjects ≥60 years (n=50/17), respectively. Multiple ascending doses were administered over two (n=45/18) and four weeks (n=10/2) to elderly only. In addition, ten healthy adults received a single dose of CNP520 under fasted and fed conditions in a cross-over fashion. Safety and tolerability were assessed based on adverse event (AE), laboratory, vital sign, ECG and other safety data. Pharmacodynamic effects were determined in elderly subjects primarily by quantification of Aβ 1-40 concentrations in cerebrospinal fluid (CSF). After single dosing, serial CSF sampling over 36h was performed. After multiple dosing, sampling was done by means of single lumbar punctures at baseline and 24h after last dose (2-week exposure) or at 2 and 4 weeks (4-week exposure). CNP520 concentrations were quantified both in plasma and CSF. CNP520 was safe and well tolerated following single and multiple doses. There was a similar incidence of AEs with CNP520 and placebo. Dose-dependent reduction of Aβ 1-40 concentrations in CSF by >90% after multiple dosing was determined. The extent of Aβ lowering was stable over four weeks of once-daily dosing. Pharmacokinetic properties included lack of relevant food effect and a terminal elimination half-life that allows once-daily dosing. The safety/tolerability, PK and PD data obtained in this FiH study support further development of CNP520 in healthy subjects at risk of Alzheimer’s disease.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jalz.2016.06.351

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 9

Metadata

Authors
Ufer, M., Rouzade-Dominguez, M.-L., Huledal, G., Pezous, N., Avrameas, A., David, O., Kretz, S., Kucher, K., Neumann, U., Cha, J.-H., Graf, A., & Lopez-Lopez, C.
Venue
Alzheimer's & Dementia
Publisher
Wiley
Published
2016-07
Volume
12
Issue
7S_Part_4
ISSN
  • 1552-5260 (ISSN-L)
  • 1552-5279
OpenAlex
W2535694483
Cited by
9
References
0
FWCI
1.14
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: O1‐10‐06: Results From a First‐in‐Human Study with the Bace Inhibitor CNP520. https://app.cochat.ai/papers/10.1016/j.jalz.2016.06.351
The paper
Ufer, M., Rouzade-Dominguez, M.-L., Huledal, G., Pezous, N., Avrameas, A., David, O., Kretz, S., Kucher, K., Neumann, U., Cha, J.-H., Graf, A., & Lopez-Lopez, C. (2016). O1‐10‐06: Results From a First‐in‐Human Study with the Bace Inhibitor CNP520. Alzheimer's & Dementia. https://doi.org/10.1016/j.jalz.2016.06.351

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.